Stockreport

Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium

Neuphoria Therapeutics Inc.  (NEUP) 
PDF Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote “FOR” BOTH of Neupho [Read more]